An unexpected result? qHBsAg and severity of fibrosis
The following research shows how difficult it is understand the complexity of Hepatitis B disease.
Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
Michelle Martinot-Peignouxa, Corresponding author contact information, E-mail the corresponding author,
Ana Carolina Ferreira Netto-Cardosoa,
a Centre de Recherche Biomédicale Bichat-Beaujon (CRB3), INSERM U-773 and Service d’Hépatologie Hôpital Beaujon APHP, Université Paris-Diderot, 92110 Clichy, France
b Roche Diagnostics Ltd., Forrenstrasse, 6343 Rotkreuz, Switzerland
c Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany
http://dx.doi.org/10.1016/j.jhep.2013.01.028, How to Cite or Link Using DOI
Permissions & Reprints
Background & aims
Little is currently known about the association between serum HBsAg or HBV DNA levels and the severity of liver disease in chronic hepatitis B (CHB) patients. Therefore, we investigated these relationships in a large cohort of unselected, well-characterized, treatment-naïve CHB patients.
CHB patients were assessed at the Hôpital Beaujon in Paris, France, between 2000 and 2008. Serum samples and liver biopsies were obtained on the same day. HBsAg, HBV DNA, and HBV genotype were investigated using commercial diagnostic assays and liver histology was scored using the METAVIR system.
406 patients were included in this cross-sectional study. Serum HBsAg and HBV DNA levels in hepatitis B e antigen-positive (HBeAg[+]) patients showed strong correlation (r=0.44, p<0.0001), as did serum HBsAg levels and fibrosis severity (r=0.43, p<0.0001). HBeAg(+) patients with moderate to severe fibrosis exhibited significantly lower serum HBsAg and HBV DNA levels compared with patients with no or mild fibrosis. Modeling analysis suggested a serum HBsAg cutoff of 3.85 log IU.mL−1 would provide a theoretical sensitivity of 100% (95% CI: 0–100), theoretical specificity of 86% (95% CI: 50–100), and a negative predictive value of 100% (95% CI: 67–100) in HBeAg(+) patients infected with HBV genotype B or C.
We found an association between low serum HBsAg levels and moderate to severe fibrosis in HBeAg(+) CHB patients. Furthermore, we describe a serum HBsAg cutoff for the prediction of fibrosis severity in CHB patients infected with HBV genotype B or C.
i think this is can be explined by the immune attack on hbv, when still hbeag positive hbsag is very high usually, probably some are able to lower it by a strong immune attack which also makes more damage to the liver
this study shows that all tests are necessary too to have a clear picture, not just hbvdna, ast-alt and a baseline biopsy like they do in US and some other countries
the very difficult disease that you can not foresee what will happen is hepatitis B.
i am naive-treatment on entecavir .5 mg since September '12 ..
i hope during few coming months we will hear about the big discovery either in west of the earth or in the east of the world that some person found a chemical compound that can kill hbsag in 5 days without any side effects .. and we will give him a Noble Prize ..
"i think this is can be explined by the immune attack on hbv, when still hbeag positive hbsag is very high usually, probably some are able to lower it by a strong immune attack which also makes more damage to the liver "
But if that is true then it would happen to all genotypes, not just two.
Would you happen to know which genotypes were included in the study (besides B and C)?
I have no access to the full paper and therefore can only give you my guesses. It was a retrospective study, I guess most of the patients in the cohort have genotype B and C, which makes sense because they are most likely to be Asians, infected at birth and maybe in the immune clearance phase when they presented at the hospital.
In Europe, most indigenous patients have genotypes A and D, and are infected as adults. I believe most of them would go straight to the immune clearance phase which tends to be shorter for them.
Whatever the explanations, I think the key point, as Stef2011 said, is don't rely on a single bio-marker and its reading at a single point in time to base a diagnosis or prognosis. A history and/or comprehensive set of tests are more accurate.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.